<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20140907019073N5</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2021-07-10</date_registration>
      <primary_sponsor>Iran University of Medical Sciences</primary_sponsor>
      <public_title>Comparison of the efficacy of platelet rich plasma injection which extracted by two methods and placebo on pain, range of motion and function of patients with osteoarthritis of the knee</public_title>
      <acronym></acronym>
      <scientific_title>A Comparative Study of the Efficacy of single and double Centrifuged platelet rich plasma and placebo (normal saline injection) on Pain, ROM and Physical Function of Patients with Knee Osteoarthritis: A Double Blinded Controlled Randomized Trial with a Three-Month Follow –up</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2021-07-23</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>45</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/52168</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Allocation of patients in treatment groups randomly using blockade with six blocks in one of the treatment groups will be as follows. A table of random numbers will be used to assign the blocks. For this purpose, one of the blocks is selected by chance and the patients are injected according to the proposed group in the block, respectively, and then the blocks are moved forward in sequence, and this process continues until the end of sampling.  Group A is single Centrifuged group, group B is double Centrifuged, group C is a placebo group (normal saline).

A:SS (single spin)
 B:DS (double spin) 
 C: P (placebo)

-Block1: AABBCC
-Block2: ABCABC
-Block3: CCBBAA
-Block4: CBACBA
-Block5: ABCCBA
-Block6: CBAABC, Blinding description: In this study, the following people will be blind of the treatment groups of patients:
Patients in the study only know that they are being injected and will not know the number of centrifuges performed.
Also, in this study, injectable interventions are performed under the supervision of a sports medicine specialist, who is not aware of the number of centrifuges performed and only injects the solution into the joint.
- Assessor Clinician: Assessments before and after interventions in the Sports Medicine Clinic will be performed by a sports medicine resident other than the researcher who does not know the presence of patients in the groups.
- Statistical Consultant and Analyzer: Analysis of research data will be performed by a statistical consultant who is not aware of patient groups.</study_design>
      <phase>N/A</phase>
      <hc_freetext>Knee Osteoarthritis.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group 1: The Group which treated by injection of platelet-rich plasma extracted single centrifuged. Preparation of PRP solution and injection will be done in the sports medicine clinic of Hazrat Rasool Akram Hospital. Patients are asked to discontinue anticoagulants and aspirin (if any) with their doctor's permission the week before the injection. To prepare PRP, kits (Arya Mabna Tashkis Corporation, RN: 312569, Rooyagen Kit) are used which have a completely sterile pack. To prepare the injection solution, 35 cc of intravenous blood from the upper limb was taken from the patients by a 50 cc syringe in which 5 cc of anticoagulant solution had already been drawn, and with the help of an 18 G needle-shaped blood transfusion adapter without any pressure on the piston into the four Sterile tube is transferred. At the same time, about 0.5 cc of the patient's blood will be sent to the laboratory of Hazrat Rasool Akram Hospital to check the amount of blood cells. All 4 tubes are filled in balance and placed in a centrifuge and rotated at 1600 RPM for 10 minutes, then they are taken out. In the group, the upper half of the isolated plasma centrifuge will be removed from all four tubes and only the lower half of the plasma will be used for injection. About 5 cc of the PRP solution prepared for injection into the 5 cc syringe is drawn with a 14G needle tip and about 0.5 cc is separated again to be sent to the laboratory. In case of pain, the patient can take acetaminophen without codeine and is not allowed to take aspirin for 10 days.  It is recommended that patients don't put weight on injected knee and doing strenuous activity for 48 hours after the injection.  One of the most important ways to treat patients with osteoarthritis of the knee is to use exercise therapy.  A common exercise protocol will be prescribed for patients with osteoarthritis of the knee participating in this study. Intervention 2: Intervention group 2: The Group which treated by injection of platelet-rich plasma extracted double centrifuged. Preparation of PRP solution and injection will be done in the sports medicine clinic of Hazrat Rasool Akram Hospital. Patients are asked to discontinue anticoagulants and aspirin (if any) with their doctor's permission the week before the injection. To prepare PRP, kits (Arya Mabna Tashkis Corporation, RN: 312569, Rooyagen Kit) are used which have a completely sterile pack. To prepare the injection solution, 35 cc of intravenous blood from the upper limb was taken from the patients by a 50 cc syringe in which 5 cc of anticoagulant solution had already been drawn, and with the help of an 18 G needle-shaped blood transfusion adapter without any pressure on the piston into the four Sterile tube is transferred. At the same time, about 0.5 cc of the patient's blood will be sent to the laboratory of Hazrat Rasool Akram Hospital to check the amount of blood cells. All 4 tubes are filled in balance and placed in a centrifuge and rotated at 1600 RPM for 10 minutes, then they are taken out. In this group, the plasma separated by the first centrifuge are drawn into the tubes and poured into two other 10 cc sterile tubes inside the box containing 0.6 cc of preservative with anti-platelet aggregation solution. It is then re-inserted and centrifuged at 3500RPM for 6 minutes. Then 3 cc end of each 2 tubes after removing the upper plasma is drawn by 5 cc syringe with 14G needle head and about 0.5 cc is separated for sending to laboratory. In case of pain, the patient can take acetaminophen without codeine and is not allowed to take aspirin for 10 days.  It is recommended that patients don't put weight on injected knee and doing strenuous activity for 48 hours after the injection.  One of the most important ways to treat patients with osteoarthritis of the knee is to use exercise therapy.  A common exercise protocol will be prescribed for patients with osteoarthritis of the knee participating in this study. Intervention 3: Control group: Therapeutic group with normal saline injection as a placebo group. In this group, 5 cc of normal saline will be injected as a placebo after blood sampling. In case of pain, the patient can take acetaminophen without codeine and is not allowed to take aspirin for 10 days.  It is recommended that patients don't put weight on injected knee and doing strenuous activity for 48 hours after the injection.  One of the most important ways to treat patients with osteoarthritis of the knee is to use exercise therapy.  A common exercise protocol will be prescribed for patients with osteoarthritis of the knee participating in this study.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Yes - There is a plan to make this available</results_IPD_plan>
      <results_IPD_description>What will be shared:
IPD collection for the primary and secondary outcomes

When:
Immediately after publication

To whom:
People working in academic institution

Conditions:
The result of further analysis may not be presented to public without permission

Where to obtain:
Mazaherinezhad.a@iums.ac.ir

How to obtain:
A reasonable request from an academic source will be responded within 10 working days

Comments:
</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Ali Mazaherinezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrate-rasool-Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 6435 2446</telephone>
        <email>mazaherinezhad.a@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Ali Mazaherinezhad</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Hazrate-rasool-Hospital</address>
        <city>Tehran</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>1449614535</zip>
        <telephone>+98 21 6435 2446</telephone>
        <email>mazaheri.a@iums.ac.ir</email>
        <affiliation>Iran University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients with grade 2 or 3 primary osteoarthritis of the knee as determined by the Kellgren and Lawrence criteria. (Associated with knee pain, morning stiffness less than 30 minutes, crepitus on movement and radiological signs of osteoarthritis include joint space loss, subchondral bone sclerosis and the formation of osteophytes in knee)
Patients aged 50-75 years.
Patients who have persistent knee pain for at least six months and with an intensity of at least 4 according to the VAS scale in activities such as going up and down stairs, sitting for long periods and squatting.
Patients who are able to walk independently for at least 30 meters.
Patients with a body mass index equal to or less than 35.
The patient has full consent to participate in the study.
The patient has a balanced mental state.</inclusion_criteria>
      <agemin>50 years</agemin>
      <agemax>75 years</agemax>
      <gender>Both</gender>
      <exclusion_criteria>The patient has a history of intra-articular injection in the knee during the last six months.
The patient has neuromuscular diseases.
The patient has a history of acute traumatic injury to other ligaments and structures of the knee joint with the approval of a specialist.
The patient has a history of surgery or previous injury in the knee and other lower limb joints over the last year.
The patient has bone implants.
The patient has a new fracture in the lower extremities during the last year.
The patient has malignant tumors.
The patient has participated in exercise therapy and physiotherapy programs during the last three months.</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>M17</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Osteoarthritis of knee</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Placebo</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group 1: The Group which treated by injection of platelet-rich plasma extracted single centrifuged. Preparation of PRP solution and injection will be done in the sports medicine clinic of Hazrat Rasool Akram Hospital. Patients are asked to discontinue anticoagulants and aspirin (if any) with their doctor's permission the week before the injection. To prepare PRP, kits (Arya Mabna Tashkis Corporation, RN: 312569, Rooyagen Kit) are used which have a completely sterile pack. To prepare the injection solution, 35 cc of intravenous blood from the upper limb was taken from the patients by a 50 cc syringe in which 5 cc of anticoagulant solution had already been drawn, and with the help of an 18 G needle-shaped blood transfusion adapter without any pressure on the piston into the four Sterile tube is transferred. At the same time, about 0.5 cc of the patient's blood will be sent to the laboratory of Hazrat Rasool Akram Hospital to check the amount of blood cells. All 4 tubes are filled in balance and placed in a centrifuge and rotated at 1600 RPM for 10 minutes, then they are taken out. In the group, the upper half of the isolated plasma centrifuge will be removed from all four tubes and only the lower half of the plasma will be used for injection. About 5 cc of the PRP solution prepared for injection into the 5 cc syringe is drawn with a 14G needle tip and about 0.5 cc is separated again to be sent to the laboratory. In case of pain, the patient can take acetaminophen without codeine and is not allowed to take aspirin for 10 days.  It is recommended that patients don't put weight on injected knee and doing strenuous activity for 48 hours after the injection.  One of the most important ways to treat patients with osteoarthritis of the knee is to use exercise therapy.  A common exercise protocol will be prescribed for patients with osteoarthritis of the knee participating in this study.</i_keyword>
      <i_keyword>Intervention group 2: The Group which treated by injection of platelet-rich plasma extracted double centrifuged. Preparation of PRP solution and injection will be done in the sports medicine clinic of Hazrat Rasool Akram Hospital. Patients are asked to discontinue anticoagulants and aspirin (if any) with their doctor's permission the week before the injection. To prepare PRP, kits (Arya Mabna Tashkis Corporation, RN: 312569, Rooyagen Kit) are used which have a completely sterile pack. To prepare the injection solution, 35 cc of intravenous blood from the upper limb was taken from the patients by a 50 cc syringe in which 5 cc of anticoagulant solution had already been drawn, and with the help of an 18 G needle-shaped blood transfusion adapter without any pressure on the piston into the four Sterile tube is transferred. At the same time, about 0.5 cc of the patient's blood will be sent to the laboratory of Hazrat Rasool Akram Hospital to check the amount of blood cells. All 4 tubes are filled in balance and placed in a centrifuge and rotated at 1600 RPM for 10 minutes, then they are taken out. In this group, the plasma separated by the first centrifuge are drawn into the tubes and poured into two other 10 cc sterile tubes inside the box containing 0.6 cc of preservative with anti-platelet aggregation solution. It is then re-inserted and centrifuged at 3500RPM for 6 minutes. Then 3 cc end of each 2 tubes after removing the upper plasma is drawn by 5 cc syringe with 14G needle head and about 0.5 cc is separated for sending to laboratory. In case of pain, the patient can take acetaminophen without codeine and is not allowed to take aspirin for 10 days.  It is recommended that patients don't put weight on injected knee and doing strenuous activity for 48 hours after the injection.  One of the most important ways to treat patients with osteoarthritis of the knee is to use exercise therapy.  A common exercise protocol will be prescribed for patients with osteoarthritis of the knee participating in this study.</i_keyword>
      <i_keyword>Control group: Therapeutic group with normal saline injection as a placebo group. In this group, 5 cc of normal saline will be injected as a placebo after blood sampling. In case of pain, the patient can take acetaminophen without codeine and is not allowed to take aspirin for 10 days.  It is recommended that patients don't put weight on injected knee and doing strenuous activity for 48 hours after the injection.  One of the most important ways to treat patients with osteoarthritis of the knee is to use exercise therapy.  A common exercise protocol will be prescribed for patients with osteoarthritis of the knee participating in this study.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Knee function with WOMAC(Western Ontario and McMaster Universities Osteoarthritis Index) scale. Timepoint: Before the intervention and one month and three months after the intervention. Method of measurement: Western Ontario and McMaster Universities Osteoarthritis Index questionnaire.</prim_outcome>
      <prim_outcome>Feeling  knee pain by Visual Analogue Scale (VAS). Timepoint: Before the intervention and one month and three months after the intervention. Method of measurement: Visual Analogue Scale (VAS).</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Knee range of motion. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: Goniometry.</sec_outcome>
      <sec_outcome>Timed Up &amp; Go test: The ability of a person to get up from a chair over a distance of 3 meters and return to the chair. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: Stopwatch (seconds).</sec_outcome>
      <sec_outcome>Six Minute Walk test: The person's ability to walk for 6 minutes. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: Distance measurement (meter).</sec_outcome>
      <sec_outcome>Stair climbing test: The ability of a person to climb stairs to reach the stage of pain or fatigue. Timepoint: Before the intervention, one month and three months after the intervention. Method of measurement: The number of steps taken.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Iran University of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2020-12-15</approval_date>
        <contact_name>Iran University of Medical Sciences</contact_name>
        <contact_address>Iran University of Medical sciences, south side of Hemmat highway, Tehran, Iran. Tehran Tehran Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
